June 1, 2026: Wegovy and GLP-1 Litigation Grows to More Than 3,700 Plaintiffs and Novo Nordisk Asks for Cases to Be Dismissed As of June 1, 2026, there are 3,763 pending claims in the GLP-1 MDL, which includes plaintiffs alleging injuries from Wegovy
Wellness & Peptide Therapy Our Wellness & Peptides program is designed to support overall health, longevity, and performance through medically supervised, prescription-based therapies
The Houston pharmaceutical injury attorneys at Reich & Binstock understand the dangers of counterfeit medications and their impact on those who unknowingly take them
More than 80% achieved at least 15% weight loss, supporting ongoing investigation in pharmacologic obesity management
Our technical support team can guide you on storage requirements and experimental conditions
This could be especially important for subjects on medications that cause bone loss, those suffering from osteopenia or osteoporosis, or those recovering from acute bone injuries